Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Evommune, Inc.NYSE: EVMN
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities falls 89.7% from a year ago
Other current liabilities stood at $1.3M at the end of Q1 FY2026, down 89.7% from a year earlier and down 71.9% from the prior quarter.
Context
- Other current liabilities amounted to 0.4% of total assets at the end of Q1 FY2026, down 22.1 pp from a year earlier.
- Other current liabilities increased in 1 of the last 2 fiscal years.
What to watch
Whether other current liabilities keeps falling in the next quarterly balance sheet after a -89.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 4.63M USD
- Year-over-year change
- -61.6%
- 2-year CAGR
- +56.6%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.63M | -61.6% |
| FY2024 | 2024-12-31 | 12.07M | +539.0% |
| FY2023 | 2023-12-31 | 1.89M | — |
Other Current Liabilities vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 other current liabilities of $1.3M is the 8th highest of the 10 companies compared; the peer median is $3.2M.
- Its year-over-year change of -89.7% is the 6th highest of 8, against a peer median of +39.2%.
- Other current liabilities amounts to 0.4% of total assets for EVMN, versus a peer median of 2.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
FTREFortrea Holdings Inc. | Jun 2026 | $380.8M | — | +4.0% | 14.0% |
| Mar 2026 | $8.89M | +58.9% | +20.6% | 3.1% | |
| Mar 2026 | $5.03M | +39.2% | -3.6% | 1.7% | |
| Mar 2026 | $3.47M | +78.9% | -34.8% | 2.6% | |
| Mar 2026 | $3.2M | -50.0% | -1.2% | 2.5% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $2.38M | +3154.8% | — | 2.2% |
CLYMClimb Bio, Inc. | Mar 2026 | $1.96M | — | — | 1.3% |
EVMNEvommune, Inc. | Mar 2026 | $1.3M | -89.7% | — | 0.4% |
| Jun 2026 | $544K | -98.6% | +2.9% | 0.0% | |
| Sep 2026 | -$11.93M | -141.7% | -15.5% | 1.0% | |
| Peer median (excluding EVMN) | $3.2M | +39.2% | -1.2% | 2.2% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.